StockWatch
·
Biotechnology: Biological Products (No Diagnostic Substances)
Loan & DebtJul 16, 2026, 04:13 PM

Inhibrx Expands Credit Facility to $500M with Oxford Finance

AI Summary

Inhibrx Biosciences, Inc. entered into a Second Amendment to its Loan and Security Agreement with Oxford Finance LLC, expanding its credit facility to an aggregate principal amount of up to $500.0 million. This amendment includes an additional tranche of $325.0 million, with $100.0 million funded immediately as a Term C Loan and up to $225.0 million available as a Term D Loan at the lenders' discretion. In connection with the Term C Loan, the company issued warrants to purchase 21,457 shares of common stock at an exercise price of $93.21 per share.

Key Highlights

  • Credit facility expanded to an aggregate principal amount of up to $500.0 million.
  • Additional tranche of $325.0 million in gross proceeds added.
  • $100.0 million (Term C Loan) funded upon execution of the Second Amendment.
  • Up to an additional $225.0 million (Term D Loan) may be funded at Lenders' discretion.
  • Issued warrants to purchase 21,457 shares for Term C Loan at $93.21 per share.
  • Warrants for Term D Loan will be 2.0% of funding, with exercise price based on market price.
  • Company pledged equity securities in Poplar Therapeutics, Inc. to Collateral Agent.